Flag of the European Union EU Clinical Trials Register Help

Clinical trials for C3a

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: C3a. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-003826-10 Sponsor Protocol Number: EAGLE Start Date*: 2014-01-24
    Sponsor Name:IRCCS- Mario Negri Institute
    Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
    Medical condition: Membranoproliferative glomerulonephritis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001440-22 Sponsor Protocol Number: 831 Start Date*: 2019-07-28
    Sponsor Name:Skåne University Hospital
    Full Title: Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting ...
    Medical condition: C3 glomerulopathy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013762-63 Sponsor Protocol Number: PRO044-CLIN-01 Start Date*: 2010-04-16
    Sponsor Name:Prosensa Therapeutics B.V
    Full Title: A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular d...
    Medical condition: Duchenne Muscular Dystrophy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: NL (Completed) BE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003402-33 Sponsor Protocol Number: CL005_168 Start Date*: 2015-02-09
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.
    Medical condition: IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024566-22 Sponsor Protocol Number: DMD114118 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subject...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013801 Duchenne muscular dystrophy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001550-22 Sponsor Protocol Number: AMY-101_SAVE Start Date*: 2020-11-04
    Sponsor Name:Amyndas Pharmaceuticals S.A.
    Full Title: A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
    Medical condition: Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2 infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003605-26 Sponsor Protocol Number: PRO044-CLIN-02 Start Date*: 2014-12-02
    Sponsor Name:Prosensa Therapeutics B.V.
    Full Title: A phase II, open label, extension study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed) SE (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004529-14 Sponsor Protocol Number: VTL-308 Start Date*: 2016-02-08
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED, PIVOTAL STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD® IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-Induced Liver Decompensation (AILD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001884-21 Sponsor Protocol Number: VTI-210 Start Date*: 2013-07-26
    Sponsor Name:VITAL THERAPIES INCORPORATED
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (SAAH) AND LILLE SCORE FAILURE
    Medical condition: Severe Acute Alcoholic Hepatitis (sAAH)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005227-37 Sponsor Protocol Number: OLT1177-10 Start Date*: 2021-03-03
    Sponsor Name:Olatec Therapeutics LLC
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of ...
    Medical condition: COVID-19, cytokine release syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001806-32 Sponsor Protocol Number: ARG-01 Start Date*: 2021-12-14
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Influence of Argipressin on blood loss and inflammatory response during hepatic resection; a double blinded, randomized, placebo-controlled trial
    Medical condition: Hepatic resection due to primary malignant disease, metastasis or benign tumour
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019701 Hepatic neoplasm malignant resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005040-10 Sponsor Protocol Number: PRO045-CLIN-01 Start Date*: 2012-12-03
    Sponsor Name:BioMarin Nederland B.V.
    Full Title: A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skipping
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Completed) GB (Completed) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003036-12 Sponsor Protocol Number: IFX-1-P2.2 Start Date*: 2016-04-22
    Sponsor Name:InflaRx GmbH
    Full Title: A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing co...
    Medical condition: Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10063101 Post procedural inflammation PT
    20.0 100000004867 10062357 SIRS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003157-27 Sponsor Protocol Number: Sobi.PEGCET-201 Start Date*: 2021-12-17
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (...
    Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005563-27 Sponsor Protocol Number: VTI-208 Start Date*: 2013-07-26
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-induced liver decompensation (AILD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004819-54 Sponsor Protocol Number: PRO051-02 Start Date*: 2008-01-22
    Sponsor Name:Prosensa Therapeutics BV
    Full Title: A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of drisapersen in patients with Duchenne muscul...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Completed) NL (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003213-34 Sponsor Protocol Number: 270-205 Start Date*: 2020-09-25
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Active or Prior Inhibitors
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001867-35 Sponsor Protocol Number: NNCIT-02 Start Date*: 2019-04-24
    Sponsor Name:TikoMed AB
    Full Title: Open, Randomized, Active Comparator-controlled, Multi-Center Study to Evaluate Safety and Efficacy of IBsolvMIR® in Islet Transplantation
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005042-35 Sponsor Protocol Number: PRO053-CLIN-01 Start Date*: 2013-08-23
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053)...
    Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by BMN 053-induced DMD exon 53 skipping
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005855-19 Sponsor Protocol Number: BCX9930-211 Start Date*: 2021-10-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
    Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 09:13:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA